{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:11:00Z","timestamp":1791274260058,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gout is a chronic inflammatory disease caused by precipitation of urate crystals in the joints, kidneys, and urinary tract. Independent of urate deposition disorders, recent studies have shown a positive association between circulating uric acid (UA) levels and cardiovascular (CV) diseases. These results indicate that UA is a precipitating factor of both gout and the progression of CV diseases, including hypertension and\/or chronic kidney disease (CKD). A large body of evidence has shown that UA-lowering therapies are effective in preventing the progression of hypertension\/CKD and that a causal relationship exists between serum UA level and CV diseases. Despite the urgent need for effective UA-lowering drugs that can be used to obtain better therapeutic outcomes and prognosis, only few drugs have been developed in the past decades. Recently, febuxostat and topiroxostat, which are xanthine oxidoreductase inhibitors, were developed and used in clinical practice. Of note, after the approval of lesinurad, which is a urate transporter-1 (URAT-1) inhibitor, in the United States in 2015, dotinurad (Fig.\u00a01), a novel promising drug with selective UA reabsorption inhibitory property, was recently developed in Japan in 2018. Dotinurad is indicated for patients with hyperuricemia\/gout as most patients with hyperuricemia are classified into \u201cunderexcretion type\u201d, which requires the inhibition of URAT-1 to excrete excess UA via the kidney. Focusing on dotinurad, the present study highlighted the multifaceted preliminary new trials that assessed for drug efficacy and safety, pharmacokinetics (PK) according to age and gender, the presence or absence of liver and kidney disorders, drug interactions with NSAID, and non-inferiority of dotinurad to either febuxostat or benzbromarone. A series of studies included in this supplemental review indicate that dotinurad reduces serum UA levels, and its efficacy and safety are similar to those of other UA-lowering agents currently used even in hyperuricemic patients with various clinical conditions. Moreover, two exploratory studies with a small sample size were conducted to compare PK parameters between patients with overproduction- and underexcretion-type hyperuricemia, and results showed that the effects of UA-lowering agents were comparable between the two subtype groups.<\/jats:p>","DOI":"10.1007\/s10157-019-01811-9","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T16:29:59Z","timestamp":1576513799000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0883-4379","authenticated-orcid":false,"given":"Satoru","family":"Kuriyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"1811_CR1","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1001\/jama.283.18.2404","volume":"283","author":"J Fang","year":"2000","unstructured":"Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971\u20131992 National Health and Nutrition Examination Survey. JAMA. 2000;283:2404\u201310.","journal-title":"JAMA."},{"key":"1811_CR2","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1161\/01.HYP.0000249768.26560.66","volume":"48","author":"PB Mellen","year":"2006","unstructured":"Mellen PB, Bleyer AJ, Erlinger TP, et al. Serum uric acid predicts incident\u00a0hypertension\u00a0in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension. 2006;48:1037\u201342.","journal-title":"Hypertension"},{"key":"1811_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/01.HYP.0000254480.64564.b6","volume":"49","author":"E Krishnan","year":"2007","unstructured":"Krishnan E, Kwoh CK, Schumacher HR, et al. Hyperuricemia and incidence of\u00a0hypertension\u00a0among men without metabolic syndrome. Hypertension. 2007;49:298\u2013303.","journal-title":"Hypertension"},{"key":"1811_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1080\/10641963.2017.1392556","volume":"40","author":"S Nishio","year":"2018","unstructured":"Nishio S, Maruyama Y, Sugano N, et al. Gender interaction of uric acid in the development of hypertension. Clin Exp Hypertens. 2018;40:446\u201351.","journal-title":"Clin Exp Hypertens"},{"key":"1811_CR5","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/hr.2012.99","volume":"35","author":"T Kawai","year":"2012","unstructured":"Kawai T, Ohishi M, Takeya Y, et al. Serum uric acid is an independent risk factor for cardiovascular disease and mortality in hypertensive patients. Hypertens Res. 2012;35:1087\u201392.","journal-title":"Hypertens Res"},{"key":"1811_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ndt\/15.1.34","volume":"15","author":"J Syrjanen","year":"2000","unstructured":"Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant. 2000;15:34\u201342.","journal-title":"Nephrol Dial Transplant"},{"key":"1811_CR7","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s10157-015-1120-4","volume":"19","author":"S Kuriyama","year":"2015","unstructured":"Kuriyama S, Maruyama Y, Nishio S, et al. Serum uric acid and the incidence of CKD and hypertension. Clin Exp Nephrol. 2015;19:1127\u201334.","journal-title":"Clin Exp Nephrol"},{"key":"1811_CR8","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","volume":"44","author":"K Iseki","year":"2004","unstructured":"Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44:642\u201350.","journal-title":"Am J Kidney Dis"},{"key":"1811_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/07853890.2016.1243803","volume":"49","author":"LH Qu","year":"2017","unstructured":"Qu LH, Jiang H, Chen JH. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. Ann Med. 2017;49:142\u201356.","journal-title":"Ann Med"},{"issue":"10","key":"1811_CR10","doi-asserted-by":"publisher","first-page":"009460","DOI":"10.1002\/14651858.cd009460.pub2","volume":"30","author":"AL Sampson","year":"2017","unstructured":"Sampson AL, Singer RF, Walters GD. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev. 2017;30(10):009460. https:\/\/doi.org\/10.1002\/14651858.cd009460.pub2.","journal-title":"Cochrane Database Syst Rev."},{"key":"1811_CR11","doi-asserted-by":"publisher","first-page":"e0187550","DOI":"10.1371\/journal.pone.0187550","volume":"12","author":"X Su","year":"2017","unstructured":"Su X, Xu B, Yan B, et al. Effects of uric acid-lowering therapy in patients with chronic kidney disease: a meta-analysis. PLoS One. 2017;12:e0187550. https:\/\/doi.org\/10.1371\/journal.pone.0187550.","journal-title":"PLoS One."},{"key":"1811_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/0886022X.2018.1456463","volume":"40","author":"X Liu","year":"2018","unstructured":"Liu X, Zhai T, Ma R, et al. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2018;40:289\u201397.","journal-title":"Ren Fail"},{"key":"1811_CR13","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s12325-015-0272-7","volume":"32","author":"C Mende","year":"2015","unstructured":"Mende C. Management of chronic kidney disease: the relationship between serum uric acid and development of nephropathy. Adv Ther. 2015;32:1177\u201391.","journal-title":"Adv Ther."},{"key":"1811_CR14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/ndt\/gft378","volume":"29","author":"B Bose","year":"2014","unstructured":"Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29:406\u201313.","journal-title":"Nephrol Dial Transplant"},{"key":"1811_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/hr.2012.135","volume":"36","author":"K Kohagura","year":"2013","unstructured":"Kohagura K, Kochi M, Miyagi T, et al. An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res. 2013;36:43\u20139.","journal-title":"Hypertens Res"},{"key":"1811_CR16","doi-asserted-by":"publisher","first-page":"F992","DOI":"10.1152\/ajprenal.00645.2016","volume":"312","author":"H Uedono","year":"2017","unstructured":"Uedono H, Tsuda A, Ishimura E, et al. U-shaped relationship between serum uric acid levels and intrarenal hemodynamic parameters in healthy subjects. Am J Physiol Renal Physiol. 2017;312:F992\u20137.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1811_CR17","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra0800885","volume":"359","author":"DI Feig","year":"2008","unstructured":"Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811\u201321.","journal-title":"N Engl J Med"},{"key":"1811_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.semnephrol.2011.08.008","volume":"31","author":"DI Feig","year":"2011","unstructured":"Feig DI. Uric acid and hypertension. Semin Nephrol. 2011;31:441\u20136.","journal-title":"Semin Nephrol"},{"key":"1811_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.metabol.2015.10.026","volume":"65","author":"W Xu","year":"2016","unstructured":"Xu W, Huang Y, Li L, et al. Hyperuricemia induces hypertension through activation of renal epithelial sodium channel (ENaC). Metabolism. 2016;65:73\u201383.","journal-title":"Metabolism."},{"key":"1811_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.amjmed.2011.11.010","volume":"125","author":"E Krishnan","year":"2012","unstructured":"Krishnan E, Lessov-Schlaggar CN, Krasnow RE, et al. Nature versus nurture in gout: a twin study. Am J Med. 2012;125:499\u2013504.","journal-title":"Am J Med"},{"key":"1811_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1017\/S0001566000006401","volume":"32","author":"JB Whitfield","year":"1983","unstructured":"Whitfield JB, Martin NG. Inheritance and alcohol as factors influencing plasma uric acid levels. Acta Genet Med Gemellol (Roma). 1983;32:117\u201326.","journal-title":"Acta Genet Med Gemellol (Roma)."},{"key":"1811_CR22","volume-title":"Japanese guideline for the management of hyperuricemia and gout","author":"Japanese Society of Gout and Nucleic Acid Metabolism","year":"2012","unstructured":"Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout. 2 [2012 suppl] ed. Osaka: Medical Review Co., Ltd; 2012.","edition":"2 [2012 suppl]"},{"key":"1811_CR23","unstructured":"NCT# 02344862."},{"key":"1811_CR24","unstructured":"NCT# 02416167."},{"key":"1811_CR25","unstructured":"NCT# 03006445."},{"key":"1811_CR26","unstructured":"NCT# 02344875."},{"key":"1811_CR27","unstructured":"NCT# 02347046."},{"key":"1811_CR28","unstructured":"NCT#0336667."},{"key":"1811_CR29","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378:1200\u201310.","journal-title":"N Engl J Med"},{"key":"1811_CR30","unstructured":"NCT# 03100318."},{"key":"1811_CR31","unstructured":"NCT#03372200."},{"key":"1811_CR32","unstructured":"NCT# 03350386."},{"key":"1811_CR33","unstructured":"NCT# 02837198."},{"key":"1811_CR34","unstructured":"NCT#3375632."},{"key":"1811_CR35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/iju.13552","volume":"25","author":"S Sakamoto","year":"2018","unstructured":"Sakamoto S, Miyazawa K, Yasui T, et al. Chronological changes in the epidemiological characteristics of upper urinary tract urolithiasis in Japan. Int J Urol. 2018;25:373\u20138.","journal-title":"Int J Urol"},{"key":"1811_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/rheumatology\/key245","volume":"58","author":"R Terkeltaub","year":"2019","unstructured":"Terkeltaub R, Saag KG, Goldfarb DS, et al. Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. Rheumatology (Oxford). 2019;58:61\u20139.","journal-title":"Rheumatology (Oxford)"}],"updated-by":[{"DOI":"10.1007\/s10157-020-01845-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000}}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01811-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-019-01811-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01811-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T04:09:09Z","timestamp":1605845349000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-019-01811-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":36,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1811"],"URL":"https:\/\/doi.org\/10.1007\/s10157-019-01811-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10157-020-01845-4","asserted-by":"object"}]},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"9 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original publication of the article the presentation of Table 1 was incorrectly published.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No conflict of interest is declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable for this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Not applicable for this review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}